Article
Metformin synergizes with gilteritinib in treating FLT3-mutated leukemia via targeting PLK1 signaling.
Cell reports. Medicine - 16 Jul 2024
Chen Meiling, Shen Chao, Chen Yi, Chen Zhenhua, Zhou Keren, Chen Yuanzhong, Li Wei, Zeng Chengwu, Qing Ying, Wu Dong, Xu Caiming, Tang Tingting, Che Yuan, Qin Xi, Xu Zhaoxu, Wang Kitty, Leung Keith, Sau Lillian, Deng Xiaolan, Hu Jianda, Wu Yong, Chen Jianjun
Abstract excerpt
Fms-like tyrosine kinase 3 (FLT3) mutations, present in over 30% of acute myeloid leukemia (AML) cases and dominated by FLT3-internal tandem duplication (FLT3-ITD), are associated with poor outcomes in patients with AML. While tyrosine kinase inhibitors (TKIs; e.g., gilteritinib) are effective, they face challenges such as drug resistance, relapse, and high costs. Here, we report that metformin, a cheap, safe,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.